What BioScrip Inc. (NASDAQ:BIOS) is not?


At the close of the recent quarter, BioScrip Inc. (NASDAQ:BIOS)‘s balance sheet demonstrated total assets worth $602.42M and debt of 22.43M%. Compared to the previous period, the debt increased/decreased by falling.

BioScrip Inc.’s total liabilities closing the latest quarter was $575.88M.

Let’s look into the technical of the stock

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching overbought territory. Be watchful of a trend reversal.

The assets that the firm listed at the close of the recent quarter comprised cash balance of 21.1M%. Net operating cash from the previous quarter was $(11.03M), resulting in free cash flow of $(12.72M). Compared to the previous period, net change in case was $11.53M.

The cash that BioScrip Inc. generated in the previous quarter stemmed from sales of 217.81M%, which increased -0.09%% in the same quarter, a year ago.

It cost BioScrip Inc. some $159.21M to generate the sales of 217.81M% reported in the previous quarter as the cost of sales. After discounting the cost of sales in the income computations, BioScrip Inc. emerged with gross income of $58.6M.

After considering other operating expenses, the firm closed with a net income figure. When that amount divided by the number of outstanding shares it closed up with EPS (earnings per share) of $(0.18). For perspective on how BioScrip Inc. reached at the EPS figure, shareholders should know that the firm closed the last quarter with diluted due shares of 118.78M.

Wall Street analysts reported investors should anticipate from BioScrip Inc. EPS of $-0.06 in the next quarter.

In addition to estimating the next quarter’s EPS, market analysts have weighed in on the stock of BioScrip Inc. regarding whether shareholders should view it as a SELL, BUY or HOLD. Some 6 analysts have analyzed the stock so far, giving it an average recommendation of Buy.